Lipocine (LPCN) Announces FDA Approval of Antares’ TLANDO
Summary: Lipocine Inc. , a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced today that Antares…
Summary: Lipocine Inc. , a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced today that Antares…
Summary : ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth control – -With this approval, the Company expects a significant reduction…
Summary : – In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of…
Synopsis : Syncona – a company focused on founding, building and funding global leaders in life science – has announced the sale…
Summary : -Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease…
Summary- Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)…
Summary : Home BancShares, Inc. (NYSE: HOMB) (“Home” or the “Company”), parent company of Centennial Bank, (“Centennial”), today announced that it has…
Summary : Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel…
Synopsis : Company announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase…
Key Point – First patient reported outcome data on Tenapanor from OPTIMIZE trial demonstrates improved overall patient experience and benefit of one…